Skip to content

Origin Stem and Logical Cup Post Market Clinical Follow-up

Origin Stem and Logical Cup Post Market Clinical Follow-up

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04123600
Enrollment
200
Registered
2019-10-11
Start date
2019-11-19
Completion date
2023-11-19
Last updated
2021-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Disease

Keywords

Hip Replacement

Brief summary

The aim of the study is to monitor the performance of the Signature Orthopaedics Origin Stem and Logical Acetabular Cup as part of post-market vigilance and continuous improvement efforts.

Detailed description

The objective of this PMCF study is to collect data confirming safety, performance and clinical benefits of the Origin Stem and Logical Cup when used for primary total hip arthroplasty at 2 years follow-up. This prospective follow-up series is necessary to obtain data specific to the Origin Stem and Logical Cup considering their relatively recent launch to the market. The study includes pre-operative, operative, discharge, 1 year post-operative and 2 year post-operative evaluations, where data concerning the performance and safety of the device are gathered. In particular, the revision rate of the components will be monitored as the primary objective, along with pre- and post-operative measurement of the Oxford Hip Score (OHS) patient-reported outcome measure (PROM) to quantify patient satisfaction, and radiographic analysis to monitor bony response to the implant and qualify the effectiveness of the cementless fixation.

Interventions

DEVICEOrigin Stem and Logical Cup

The Origin Stem is a straight, tapered, HA coated cementless femoral stem, and the Logical Cup is a porous coated acetabular cup mated with a cross-linked polyethylene liner. The components are used as part of a total joint replacement prosthesis.

Sponsors

The Cleveland Clinic
CollaboratorOTHER
Signature Orthopaedics
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* patient requires unilateral primary total hip arthroplasty due to non-inflammatory degenerative joint disease (e.g. osteoarthritis, traumatic arthritis, avascular necrosis, dysplasia/DDH) * patient must be a candidate for use of the products studied, as determined jointly by the surgeon and patient * male and non-pregnant female patients aged 18-75 * patients who understand the conditions of the clinical evaluation and are willing to participate for the length of the prescribed follow-up

Exclusion criteria

* patient has active infection or sepsis (treated or untreated) * patient has any vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery. * patient is female of child-bearing age and not taking contraceptive precautions * patient has inadequate bone stock to support the device (e.g. severe osteopenia, family history of severe osteoporosis or osteopenia) * patient has inflammatory joint disease (e.g. rheumatoid arthritis) * patient has known moderate to severe renal deficiency * patient has a known or suspected metal sensitivity * patient is immuno-suppressed with diseases such as AIDS or is receiving high dose of corticosteroids * patient has an emotional or neurological condition that would pre-empt their ability or unwillingness to participate in the clinical evaluation including mental illness, mental retardation or drug abuse * patient is severely overweight with a BMI\>40.

Design outcomes

Primary

MeasureTime frameDescription
Stem and Cup Survival Rateup to 2 yearsThe implant survival rate based on removal of the device for any reason as determined following the Kaplan-Meier method.

Secondary

MeasureTime frameDescription
Oxford Hip Score (OHS)up to 2 yearsThe OHS is a patient reported outcome measure (PROM) used to quantify patient satisfaction with the treatment, consisting of 12 questions scored 1 to 5 by the patient.
Radiographic Analysisup to 2 yearsPost-operative radiographs of the implant are analysed to identify locations and sizes of radiolucencies, indicative of poor fixation. The size, location and progression of radiolucencies is monitored. Smaller, non-progressive radiolucencies are preferred.

Countries

United States

Contacts

Primary ContactMelody C Labrune, MS
melody.labrune@signatureortho.com.au+61 02 9428 5181
Backup ContactDeclan Brazil, PhD
declan@signatureortho.com.au+61 02 9428 5181

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026